Peginterferon alfa-2a
- Generic Name
- Peginterferon alfa-2a
- Brand Names
- Pegasys
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 198153-51-4
- Unique Ingredient Identifier
- Q46947FE7K
- Background
Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting...
- Indication
Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease . May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
...
- Associated Conditions
- Chronic Hepatitis B Infection, Chronic Hepatitis C Virus (HCV) Infection, HBeAg Positive Chronic Hepatitis B
- Associated Therapies
- -
S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2013-07-05
- Target Recruit Count
- 24
- Registration Number
- NCT00475176
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B
- First Posted Date
- 2007-02-16
- Last Posted Date
- 2016-10-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 39
- Registration Number
- NCT00436163
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3
- Conditions
- Interventions
- First Posted Date
- 2006-12-14
- Last Posted Date
- 2013-08-08
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 933
- Registration Number
- NCT00411385
- Locations
- 🇺🇸
Atlanta Gastroenterology Associates, Atlanta, Georgia, United States
🇺🇸Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients
- Conditions
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2013-08-08
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 1331
- Registration Number
- NCT00402428
- Locations
- 🇺🇸
University of New Mexico, Albuquerque, New Mexico, United States
🇺🇸Maryland Digestive Disease Center, Laurel, Maryland, United States
🇦🇺Monash Medical Centre, Clayton, Victoria, Australia
A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2006-10-31
- Last Posted Date
- 2010-08-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1175
- Registration Number
- NCT00394277
High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV
- Conditions
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Foundation for Liver Research
- Target Recruit Count
- 33
- Registration Number
- NCT00381953
- Locations
- 🇳🇱
Erasmus Medical Center, Rotterdam, Netherlands
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection
- Conditions
- Interventions
- First Posted Date
- 2006-07-18
- Last Posted Date
- 2010-08-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 415
- Registration Number
- NCT00353418
Continuing Treatment With Pegasys and Copegus
- Conditions
- First Posted Date
- 2006-06-13
- Last Posted Date
- 2006-06-13
- Lead Sponsor
- Májbetegekért Alapítvány
- Target Recruit Count
- 100
- Registration Number
- NCT00336518
- Locations
- 🇭🇺
Szt. László Hospital, Budapest, Hungary
Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C
- Conditions
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 12
- Registration Number
- NCT00262483
- Locations
- 🇵🇷
Call for information, Santurce, Puerto Rico
Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2009-02-18
- Lead Sponsor
- University Hospital, Bonn
- Target Recruit Count
- 2
- Registration Number
- NCT00221286
- Locations
- 🇩🇪
Praxiszentrum Kaiserdamm, Berlin, Germany
🇩🇪Immunologische Ambulanz, Medizinische Klinik und Poliklinik I, Bonn University, Bonn, North-Rhine Westfalia, Germany
🇩🇪Abteilung Klinische Immunologie Zentrum Innere Medizin der Medizinischen Hochschule Hannover, Hannover, Lower Saxony, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.